Growth arrest and apoptosis induced by kinesin Eg5 inhibitor K858 and by its 1,3,4-thiadiazoline analogue in tumor cells
- 1 August 2018
- journal article
- research article
- Published by Wolters Kluwer Health in Anti-Cancer Drugs
- Vol. 29 (7) , 674-681
Abstract
Tumors are complex and heterogeneous but, despite this, they share the ability to proliferate continuously, irrespective of the presence of growth signals, leading to a higher fraction of actively growing and dividing cells compared with normal tissues. For this reason, the cytotoxic antimitotic treatments remain an important clinical tool for tumors. Among these drugs, antitubulin compounds constitute one of the most effective anticancer chemotherapies; however, they cause dose-limiting side effects. Therefore, it is still necessary to develop compounds with new targets and new mechanisms of action to reduce side effects or chemoresistance. Mitosis-specific kinesin Eg5 can represent an attractive target for discovering such new anticancer agents because its role is fundamental in mitotic progression. Therefore, we analyzed the effects induced by an inhibitor of kinesin Eg5, K858, and by its 1,3,4-thiadiazoline analogue on human melanoma and prostate cancer cell lines. We found that both compounds have an antiproliferative effect, induce apoptosis, and can determine a downmodulation of survivin.Keywords
This publication has 45 references indexed in Scilit:
- Selective killing of p53‐deficient cancer cells by SP600125EMBO Molecular Medicine, 2012
- The proliferation rate paradox in antimitotic chemotherapyMolecular Biology of the Cell, 2012
- Impacting tumor cell-fate by targeting the inhibitor of apoptosis protein survivinMolecular Cancer, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- How kinesin motor proteins drive mitotic spindle function: Lessons from molecular assaysSeminars in Cell & Developmental Biology, 2010
- A phase I study of ispinesib, a kinesin spindle protein inhibitor, administered weekly for three consecutive weeks of a 28-day cycle in patients with solid tumorsInvestigational New Drugs, 2010
- Kinase Signaling in the Spindle CheckpointJournal of Biological Chemistry, 2009
- Kinesin Spindle Protein (KSP) Inhibitors. 9. Discovery of (2S)-4-(2,5-Difluorophenyl)-N-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-(hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide (MK-0731) for the Treatment of Taxane-Refractory CancerJournal of Medicinal Chemistry, 2008
- The BCL-2 protein family: opposing activities that mediate cell deathNature Reviews Molecular Cell Biology, 2008
- Small Molecule Inhibitor of Mitotic Spindle Bipolarity Identified in a Phenotype-Based ScreenScience, 1999